New Developments for Parkinson’s Therapy with Comt Inhibitors

Disclosure: Prof Heinz Reichmann received research grants and compensation for his involvement on advisory boards and lectures from Abbott, Abbvie, Bayer Health Care, BIAL, Boehringer/Ingelheim, Brittania, Cephalon, Desitin, GSK, Lundbeck, Medtronic, Merck-Serono, Novartis, Orion, Pfizer, TEVA, UCB Pharma, Valeant, and Zambon. Prof Werner Poewe has received honoraria for lectures and consultancy fees in relation to clinical drug development programmes for Parkinson’s disease from AbbVie, Allergan, AstraZeneca, BIAL, Boehringer Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Novartis, Orion Pharma, Teva, UCB, and Zambon. He also received royalties from Thieme, Wiley Blackwell, Oxford University Press, and Cambridge University Press. Prof Georg Ebersbach has received honoraria for consulting from AOK Nordost and in his capacity as advisor for AbbVie Pharma, Grünenthal Pharma, and UCB Pharma. Furthermore, he received honoraria for speaker engagements from AbbVie Pharma, BIAL Pharma, Britannia Pharma, Desitin Pharma, Grünenthal Pharma, Licher GmbH, Mundipharma, TEVA Pharma, UCB Pharma, and Zambon Pharma. Prof Ebersback also receives royalties from Kohlhammer Verlag. Prof Thomas Müller has received honoraria from BIAL. Acknowledgements: Writing assistance provided by Dr Juliane Moloney, ApotheCom, London, UK. Support: Jan Jastorff translated the transcript of the presentation and BIAL/Basilio Hernandes carried out a review for medical accuracy. The satellite symposium and the publication of this article were funded by BIAL-Portela & Ca., S.A. The views and opinions expressed are those of the authors and not necessarily of BIAL-Portela & Ca., S.A. Citation: EMJ Neurol. 2017;5[Suppl 1]:2-10.